Nine-year change in statistical design, profile, and success rates of Phase II oncology trials

ABSTRACT We investigated nine-year trends in statistical design and other features of Phase II oncology clinical trials published in 2005, 2010, and 2014 in five leading oncology journals: Cancer, Clinical Cancer Research, Journal of Clinical Oncology, Annals of Oncology, and Lancet Oncology. The features analyzed included cancer type, multicenter vs. single-institution, statistical design, primary endpoint, number of treatment arms, number of patients per treatment arm, whether or not statistical methods were well described, whether the drug was found effective based on rigorous statistical testing of the null hypothesis, and whether the drug was recommended for future studies.

[1]  Olga V. Marchenko,et al.  Monitoring rules for toxicity in Phase II oncology trials , 2015 .

[2]  A. Jemal,et al.  Cancer statistics, 2015 , 2015, CA: a cancer journal for clinicians.

[3]  Tae Min Kim,et al.  Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Jubilee Brown,et al.  Pemetrexed and cisplatin for the treatment of advanced, persistent, or recurrent carcinoma of the cervix: a limited access phase II trial of the gynecologic oncology group. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  N. Schmitz,et al.  Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial. , 2014, The Lancet. Oncology.

[6]  A. Ravaud,et al.  Phase II Results of Dovitinib (TKI258) in Patients with Metastatic Renal Cell Cancer , 2014, Clinical Cancer Research.

[7]  F. Vera-Badillo,et al.  Benefit and Harms of New Anti-Cancer Drugs , 2013, Current Oncology Reports.

[8]  Martin Schumacher,et al.  Competing Risks and Multistate Models , 2012, Clinical Cancer Research.

[9]  Michael Branson,et al.  A proof of concept phase II non‐inferiority criterion , 2011, Statistics in medicine.

[10]  Michael R Hamblin,et al.  CA : A Cancer Journal for Clinicians , 2011 .

[11]  J. Hainsworth,et al.  Bevacizumab and everolimus in the treatment of patients with metastatic melanoma , 2010, Cancer.

[12]  Susan Groshen,et al.  The Design of Phase II Clinical Trials Testing Cancer Therapeutics: Consensus Recommendations from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee , 2010, Clinical Cancer Research.

[13]  K. Gelmon,et al.  Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[15]  J. Grill,et al.  Topotecan as a radiosensitizer in the treatment of children with malignant diffuse brainstem gliomas , 2005, Cancer.

[16]  Hua Jin,et al.  A design of phase II cancer trials using total and complete response endpoints , 2005, Statistics in medicine.

[17]  W. London,et al.  One‐ and two‐stage designs for stratified phase II clinical trials , 2005, Statistics in medicine.

[18]  C. Yiannoutsos,et al.  Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a phase II Hoosier Oncology Group study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  A Kramar,et al.  Five-year change in statistical designs of phase II trials published in leading cancer journals. , 2004, European journal of cancer.

[20]  E. Eisenhauer,et al.  Application of a new multinomial phase II stopping rule using response and early progression. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  D. Sargent,et al.  A three-outcome design for phase II clinical trials. , 2001, Controlled clinical trials.

[22]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[23]  E Marubini,et al.  Content and quality of currently published phase II cancer trials. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  T T Chen,et al.  Optimal flexible designs in phase II clinical trials. , 1998, Statistics in medicine.

[25]  J. Bryant,et al.  Incorporating toxicity considerations into the design of two-stage phase II clinical trials. , 1995, Biometrics.

[26]  P. Bauer,et al.  Evaluation of experiments with adaptive interim analyses. , 1994, Biometrics.

[27]  J Benichou,et al.  Application of the triangular test to phase II cancer clinical trials. , 1990, Statistics in medicine.

[28]  R. Simon,et al.  Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.

[29]  R. Wittes,et al.  Methodologic guidelines for reports of clinical trials. , 1985, Cancer treatment reports.

[30]  T R Fleming,et al.  One-sample multiple testing procedure for phase II clinical trials. , 1982, Biometrics.

[31]  E. Gehan,et al.  The determinatio of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. , 1961, Journal of chronic diseases.